Skip to content
Screener

Crinetics Pharmaceuticals CRNX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$57.3M+25.7%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$1.92M+88.5%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$178K+36.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.32M-30.7%
XER
Xeris Biopharma Holdings, Inc.XERS
$6.31M+2.5%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$0-100%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.92B+246%
Enterprise value$8.85B+244%
P/S493.7×-1,359×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0×0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemMarch 31,2026December 31,2025
Accounts payable and accrued expenses$37,487$41,770
Accrued compensation and related expenses25,79235,578
Deferred revenue1,2711,235
Operating lease liabilities6,5366,489
Total current liabilities71,08685,072
Operating lease liabilities, non-current41,31942,052
Deferred revenue, non-current3,3463,810
Other liabilities4,9263,240

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's operating lease liabilities (current)?
Crinetics Pharmaceuticals (CRNX) reported operating lease liabilities (current) of $6.54M in Q1 2026.
How has Crinetics Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
Crinetics Pharmaceuticals's operating lease liabilities (current) decreased by 5.0% year-over-year, from $6.88M to $6.54M.
What is the long-term trend for Crinetics Pharmaceuticals's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's operating lease liabilities (current) has grown at a 50.7% compound annual growth rate (CAGR), from $835K to $6.49M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Crinetics Pharmaceuticals's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude